International Journal of Clinical Pharmacy

, Volume 36, Issue 4, pp 795–799 | Cite as

Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients

  • Ryuichi Hirano
  • Yuichi Sakamoto
  • Naoki Tachibana
  • Motoki Ohnishi
Research Article


Background Thrombocytopenia is a major side effect of linezolid therapy. However, there are few reports about the risk factors for linezolid-induced thrombocytopenia. Objective The aim of this study is to evaluate the risk factors for thrombocytopenia in patients who undergo linezolid therapy. Setting Aomori Prefectural Central Hospital in Japan, a tertiary 695 beds hospital. Method A retrospective review was performed using the hospital’s medical records. From January 2010 to August 2012, 75 adult patients who received linezolid therapy were enrolled in this study. Main outcome measure Linezolid-induced thrombocytopenia was defined as a decrease in the patient’s platelet count to <10 × 104/μL or a reduction of ≥30 % from their baseline value. Odds ratios (OR) for thrombocytopenia were analyzed using multivariate stepwise logistic regression analysis. Results Thrombocytopenia occurred in 29 patients (38.6 %), seven of whom required platelet transfusions. The patients who developed thrombocytopenia were significantly older, displayed a significantly higher frequency of renal insufficiency, and received linezolid therapy for significantly longer than the patients without thrombocytopenia. Stepwise logistic regression analysis suggested that receiving linezolid therapy for ≥14 days was a significant risk factor for thrombocytopenia [OR 13.3, 95 % confidence interval (CI) 3.2–55.6, p < 0.01], whereas the creatinine clearance rate exhibited a significant negative correlation with the incidence of the condition [OR 0.98, 95 % CI 0.96–0.99, p = 0.037]. The incidence of thrombocytopenia among the patients who demonstrated creatinine clearance rates of <30 mL/min was 60 % (12/20), which was significantly higher than that observed among the patients who displayed creatinine clearance rates of more than 60 mL/min (26.4 %, 9/34, p = 0.014). Conclusion Receiving linezolid therapy for ≥14 days and a low creatinine clearance rate were suggested to be risk factors for linezolid-induced thrombocytopenia. The platelet counts of patients with these risk factors should be closely monitored.


Adverse effect Creatinine clearance Japan Linezolid Thrombocytopenia 



We thank Kumiko Kudo (Chief Pharmacist, Aomori Prefectural Central Hospital) for her comments on this article.



Conflicts of interest

There are no conflicts of interest associated with this manuscript.


  1. 1.
    Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;138(2):135–42.PubMedCrossRefGoogle Scholar
  2. 2.
    Vallani P, Regazzi M, Marubbi F, Viale P, Pagani P, Cristini F, et al. Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother. 2002;46(3):936–7.CrossRefGoogle Scholar
  3. 3.
    Lovering A, Zhang J, Bannister G, Lankester J, Brown J, Narendra G, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother. 2002;50(1):73–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Brier M, Stalker D, Aronoff G, Batts D, Ryan K, O’Grady M, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003;47(9):2775–80.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Takahashi Y, Takesue Y, Nakajima K, Ichiki K, Tsuchida T, Tatsumi S, et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother. 2011;17(3):382–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Kobayashi T, Sadoh S, et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother. 2011;17(1):70–5.PubMedCrossRefGoogle Scholar
  7. 7.
    De Vriese AS, Coster RV, Smet J, Seneca S, Lovering A, Van Haute LL, et al. Linezolid induced inhibition of mitochondrial protein synthesis. Clin Infect Dis. 2006;42(8):1111–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ. Mechanism for linezolid induced anemia and thrombocytopenia. Ann Pharmacother. 2003;37(4):517–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Niwa T, Suzuki A, Sakakibara S, Kasahara S, Yasuda M, Fukao A, et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther. 2009;31(10):2126–33.PubMedCrossRefGoogle Scholar
  10. 10.
    National Cancer Institute, Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v4.0. Accessed 10 Feb 2014.
  11. 11.
    Ikuta S, Tanimura K, Yasui C, Aihara T, Yoshie H, Iida H, et al. Chronic liver diseases increases the risk of linezolid related thrombocytopenia in methicillin-resistant Staphylococcus aureus infected patients after digestive surgery. J Infect Chemother. 2011;17(3):388–91.PubMedCrossRefGoogle Scholar
  12. 12.
    Slatter J, Stalker J, Feenstra K, Welshman I, Bruss J, Sams J, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14C]linezolid to healthy human subjects. Drug Metab Dispos. 2001;29(8):1136–45.PubMedGoogle Scholar
  13. 13.
    Matsumoto K, Takeshita A, Ikawa K, Shigemi A, Yaji K, Shimodozono Y, et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents. 2010;36(2):179–81.PubMedCrossRefGoogle Scholar
  14. 14.
    Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, Suzuki H, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013;68(9):2128–33.PubMedCrossRefGoogle Scholar
  15. 15.
    Sasaki T, Takane H, Ogawa K, Isagawa S, Hirota T, Higuchi S, et al. Population pharmacokinetic and pharmacodynamics analysis of linezolid and hematologic side effect, thrombocytopenia Japanese patients. J Antimicrob Chemother. 2011;55(5):1867–73.CrossRefGoogle Scholar
  16. 16.
    Federico P, Pierluigi V, Piergiorgio C, Barbara P, Eleonora Z, Mario F. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012;67(3):2034–42.Google Scholar
  17. 17.
    Ishida S, Maeda K, Nishio C, Nakai Y. Risk factors of linezolid associated thrombocytopenia. Jpn J Chemother. 2013;61(1):1–4.Google Scholar
  18. 18.
    Nimish P, Hillary V, Linda T, Antonio R, Benjamin W, Amanda D, et al. A comparative evaluation of adverse platelet outcomes among veterans affairs patients receiving linezolid or vancomycin. J Antimicrob Chemother. 2012;67(3):727–35.CrossRefGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2014

Authors and Affiliations

  • Ryuichi Hirano
    • 1
  • Yuichi Sakamoto
    • 2
  • Naoki Tachibana
    • 2
  • Motoki Ohnishi
    • 3
  1. 1.Department of PharmacyAomori Prefectural Central HospitalAomoriJapan
  2. 2.Department of Laboratory Medicine and Blood transfusionAomori Prefectural Central HospitalAomoriJapan
  3. 3.Department of General MedicineAomori Prefectural Central HospitalAomoriJapan

Personalised recommendations